10.1016/s1470-2045(16)30631-3 - Tumour-infiltrating lymphocytes in ad...

This document has been corrected

Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study

10.1016/s1470-2045(16)30631-3

Published Online: 2017-01-?

Journal: The Lancet Oncology•Publisher: Elsevier BV

Authors: Astrid Kiermaier•Emma Clark•Jennifer Eng-Wong•Jose Baselga•Peter Savas•Roberto Salgado•Sandra M Swain•Sherene Loi•Stefan Michiels•Stephen Fox•Stephen J Luen

This document has been corrected

Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study

10.1016/s1470-2045(16)30631-3

Published Online: 2017-01-?

Journal: The Lancet Oncology

Authors: Astrid Kiermaier•Emma Clark•Jennifer Eng-Wong•Jose Baselga•Peter Savas•Roberto Salgado•Sandra M Swain•Sherene Loi•Stefan Michiels•Stephen Fox•Stephen J Luen

NOW

2018-12-01•Erratum

Correction to Lancet Oncol 2017; 18: 52–62

10.1016/s1470-2045(18)30850-7

* information provided by CrossRef

2018-12-01•Erratum

10.1016/s1470-2045(18)30850-7

* information provided by CrossRef

2017-01-?•Published

2018-12-01•Erratum

Correction to Lancet Oncol 2017; 18: 52–62

10.1016/s1470-2045(18)30850-7

* information provided by CrossRef

This document has been corrected

Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study

10.1016/s1470-2045(16)30631-3

Published Online: 2017-01-?

Journal: The Lancet Oncology•Publisher: Elsevier BV

Authors: Astrid Kiermaier•Emma Clark•Jennifer Eng-Wong•Jose Baselga•Peter Savas•Roberto Salgado•Sandra M Swain•Sherene Loi•Stefan Michiels•Stephen Fox•Stephen J Luen